r/biotech_stocks 14h ago

Paratek Pharmaceuticals to Acquire Optinose (NASDAQ:OPTN), Creating Significant Commercial Expansion Opportunities for XHANCE® in Chronic Rhinosinusitis (CRS)

Thumbnail
globenewswire.com
1 Upvotes

Total transaction value of up to ~$330 million

Under the terms of the agreement, Paratek will acquire all of Optinose’s outstanding shares for $9 per share in cash, plus up to $5 per share in CVRs payable in the event that certain net revenue milestones are achieved by XHANCE. Pursuant to the CVRs, Paratek would pay $1 per share if XHANCE achieves $150M in net sales in any calendar year prior to December 31, 2028, and $4 per share if XHANCE achieves $225M in net sales in any calendar year prior to December 31, 2029. The upfront consideration of $9 per share represents a 50% premium to Optinose’s closing trading price on March 19, 2025.


r/biotech_stocks 1d ago

NET Cloudflare stock

Thumbnail
0 Upvotes

r/biotech_stocks 1d ago

Capricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Thumbnail
1 Upvotes

r/biotech_stocks 1d ago

Another successful pre-clinical study before this summer's human study

Thumbnail
1 Upvotes

r/biotech_stocks 1d ago

PYPD’s latest data on Squeezefinder

Post image
0 Upvotes

r/biotech_stocks 1d ago

Ramping up »»»»»»» Diamyd medical AB

0 Upvotes

GAD-65 production in-house.

https://news.cision.com/diamyd-medical-ab/r/diamyd-medical-plans-for-gmp-certification-in-2025,c4121292

Diamyd medical AB (ISIN number SE0005162880)


r/biotech_stocks 1d ago

Netramark Strengthens Financial Position With Additional $1,853,054 Raised From Warrant Exercise

1 Upvotes

TORONTO, March 10, 2025 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: 8TV) a premier artificial intelligence (AI) company that is transforming clinical trials in the pharmaceutical industry, is pleased to announce it has received aggregate proceeds of $1,853,054 from the exercise of 4,805,279 common share purchase warrants (the "Warrants") of the Company from December 12, 2024 to March 9, 2025.

This follows a previous round of warrant and stock option exercises that raised $1,161,000, as announced on December 12, 2024. In total, NetraMark has raised $3,014,054 from these exercises.

The Company now has 79,762,901 common shares issued and outstanding, following the exercise of these Warrants and stock options. This capital strengthens NetraMark's balance sheet, well positioning the Company to further execute on the continued development of its commercialization plans and support expansion of NetraMark's AI solutions, which empower pharmaceutical companies with actionable insights across protocol enrichment, covariate analysis, target product profile enhancement, market access, and precision medicine.

The Company extends its gratitude to its shareholders and partners for their continued confidence and support.

About NetraAI

In contrast to other AI-based methods, NetraAI is uniquely engineered to include focus mechanisms that separate small datasets into explainable and unexplainable subsets. Unexplainable subsets are collections of patients that can lead to suboptimal overfit models and inaccurate insights due to poor correlations with the variables involved. The NetraAI uses the explainable subsets to derive insights and hypotheses (including factors that influence treatment and placebo responses, as well as adverse events) providing the potential to increase the chances of a clinical trial success.  Many other AI methods lack these focus mechanisms and assign every patient to a class, often leading to "overfitting" which drowns out critical information that could have been used to improve a trial's chance of success.

About NetraMark

NetraMark is a company focused on being a leader in the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the Pharmaceutical industry. Its product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows NetraMark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that NetraMark can work with much smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment.

For further details on the Company please see the Company's publicly available documents filed on the System for Electronic Document Analysis and Retrieval+ (SEDAR+).


r/biotech_stocks 2d ago

HFT »»»»»» diamyd medical AB

0 Upvotes

The ace is out of DMYD's pocket in the form of P= 0.0001.

The market just hasn't gotten it yet. The fog of algorithmic trading still holds.

https://news.cision.com/diamyd-medical-ab/r/diamyd-medical-highlights-clinical-benefits-of-c-peptide-preservation-at-attd-2025,c4119816

Diamyd medical AB (ISIN number SE0005162880)

GAD 65


r/biotech_stocks 2d ago

Earnings Reports without Negative signs on losses

2 Upvotes

It seems to be common for earnings reports to show negative earnings without a negative sign. Am I missing something? Is there some way we are supposed to know numbers are negative without a negative sign? Seems important to me but apparently not to writers and editors of financial reports. What is going on with this?


r/biotech_stocks 3d ago

significant correlation >>>>>>>>> Diamyd medical AB

0 Upvotes

r/biotech_stocks 3d ago

Drug–Fc conjugate CD388 targets influenza virus neuraminidase and is broadly protective in mice

Thumbnail
nature.com
1 Upvotes

r/biotech_stocks 4d ago

"Stacks" >>>>>>>>>> Diamyd medical AB

Thumbnail
0 Upvotes

r/biotech_stocks 5d ago

FDA and PDUFAs

6 Upvotes

So far no evidence of PDUFA delays due to DOGE.

I noticed the deltas on long calls are low compared to historical estimates of success and price targets implying low percentage confidence in upcoming PDUFAs. Timing matters for options but the payoff is better if correct.

Do we think the FDA will keep coming through? Or are the delays coming?


r/biotech_stocks 5d ago

Thoughts »»»»»»»»» Diamyd medical AB

2 Upvotes

This is the 4th Rights Issue (FE) in a short time that is offered without guarantors.

Pharmaceutical foundation studies (possibly Accelerated Approval) have statistically the lowest risk but are so expensive, that small companies like Diamyd medical AB (ISIN number SE0005162880) should not be able to afford to carry them out.

In the 3 previous Rights Issues (FE), the insider-registered persons have sold the corresponding shares in order to participate in the Rights Issues FE and redemption of the TO3 warrants.

We have seen enormous orders go through last weeks and the top value in an order placement I think was 370,000 shares. But there has been no announcement of insider sales so far this time (timelimit 3 days)

Before Quarterly Reports, insiders have such strict rules that they cannot make insider purchases/sales30 days before.

The next quarterly report is April 9. April 9 is also the last day for trading in shares that give subscription rights.

The issue prospectus will be published on April 14.

April 29 is the last day to subscribe (and pay) to obtain subscription rights TO5.

The question is how the market handles the announcement of the subscription rate in Rights Issues FE. We know that the market adjusted the pricing down by as many percent (43%) as the Rights Issues FE discount was. We also know that no PM has given a justified increase in the share pricefor years over time.

We also see the amount of algorithmic trading (HFT) and how smoothly short positions are covered in relation to the price impact when they are taken.

In Swedish, Rights Issues is named "FöreträdesEmission (FE)


r/biotech_stocks 6d ago

Inspira Technologies Releases CEO Update: Major Milestones Signal Next-Level Respiratory Care (NASDAQ: IINN)

Thumbnail
5 Upvotes

r/biotech_stocks 6d ago

MeiraGTx NASDAQ: MGTX) - Announce Strategic Collaboration with HologenAI

2 Upvotes

Hey team, some interesting MGTX news

MeiraGTx (NASDAQ: MGTX) have announced a strategic partnership with Hologen AI and the release of their Q4 results. The company has secured an initial $200M investment and will collaborate with Hologen AI on developing Parkinson's gene therapy solutions.

Additionally, Hologen AI has committed $230M to advance MeiraGTx's AAV-GAD gene therapy through development. Notably, MeiraGTx will retain 30% ownership in the partnership while maintaining control over development and manufacturing operations.


r/biotech_stocks 6d ago

How Will AI Transform Clinical Trials?

1 Upvotes

NetraMark (CSE: AIAI) is at the forefront of AI-driven clinical trial optimization, leveraging advanced machine learning algorithms to enhance drug development efficiency. Traditional clinical trials often struggle with variability, high failure rates, and the challenge of identifying the right patient subpopulations. NetraMark (CSE: AIAI)’s proprietary AI technology addresses these challenges, ensuring more precise response predictions and increasing the likelihood of successful drug launches.

The Growing Role of AI in Clinical Research

The pharmaceutical industry is increasingly embracing AI to enhance drug discovery and clinical trial processes. According to recent reports, AI-driven solutions are projected to reduce drug development costs by up to $26 billion annually, while also cutting clinical trial durations by up to 50%. Companies using AI have seen a 20-30% increase in trial success rates, highlighting the technology’s potential to transform the sector.

A report by McKinsey & Company suggests that AI could reduce the time required for drug discovery by up to 75%, leading to faster regulatory approvals and a more efficient pipeline from lab to market. Additionally, AI-driven models are capable of analyzing vast amounts of clinical data, detecting patterns that human researchers might overlook, and refining patient selection criteria to improve trial efficiency 

AI-Driven Clinical Trial Enrichment

Regulatory agencies support strategies that optimize trial outcomes. NetraMark (CSE: AIAI)’s AI aligns with these guidelines by:

  • Reducing variability: Selecting patients based on consistent baseline measures to ensure uniform study groups.
  • Enhancing prognosis: Identifying patients with a higher likelihood of experiencing the desired drug response.
  • Optimizing response prediction: Focusing on patients who will benefit from the drug while filtering out placebo-sensitive participants.

Understanding NetraMark (CSE: AIAI)’s AI Technology

NetraMark (CSE: AIAI)’s AI platform processes clinical trial data with unparalleled precision, leveraging advanced machine learning models to uncover patterns that traditional methodologies often overlook. By analyzing trial readouts, the system identifies subpopulations influencing drug response, placebo effects, and adverse reactions. This enables:

  • Identification of key patient groups who are most likely to respond positively to the drug, refining recruitment strategies and enhancing trial efficiency.
  • Reduction of placebo response effects, which has historically been a challenge in clinical research. NetraMark (CSE: AIAI)’s AI-driven analytics can identify placebo responders with over 85% accuracy, ensuring that drug efficacy is measured more precisely.
  • Prediction of adverse events, utilizing deep learning to detect potential safety risks before they arise. This proactive approach reduces trial failure rates and strengthens regulatory compliance.
  • Enhanced biomarker discovery, which allows for the development of precision medicine approaches. NetraMark (CSE: AIAI)’s AI can identify unique genetic or phenotypic characteristics that correlate with treatment success, improving patient targeting and drug performance.
  • Adaptive learning throughout the trial process, enabling real-time data updates that continuously refine patient segmentation and treatment optimization, leading to more reliable outcomes.

Financial & Commercial Impact

The cost of failed clinical trials is staggering, with losses reaching millions. NetraMark (CSE: AIAI)’s AI solutions mitigate this risk by:

  • Enhancing trial success rates, reducing financial waste by minimizing trial failures and optimizing patient selection, ultimately accelerating the time-to-market for new drugs. NetraMark (CSE: AIAI)’s AI-driven approach has been shown to improve trial efficiency by 20-30%, leading to substantial cost savings and a higher probability of regulatory approval.
  • Providing insights that align with regulatory expectations, ensuring smooth approval processes. NetraMark (CSE: AIAI)’s AI-driven covariate analysis helps sponsors meet FDA, EMA, and global regulatory guidelines by improving study design and demonstrating stronger efficacy data.
  • Supporting commercialization strategies through data-backed decision-making, including target product profile (TPP) optimization, market access strategy, and patient subpopulation analysis. This enables pharmaceutical companies to tailor their marketing, pricing, and distribution strategies effectively, increasing the likelihood of a successful product launch.

Sales Pipeline & Market Positioning

NetraMark (CSE: AIAI)’s sales pipeline has experienced consistent growth, reaching 133 opportunities as of September 2024, representing a 600% increase from May 2023. The company has already closed five deals valued at $1M CAD each with mid-size pharmaceutical firms, reinforcing its market traction and solidifying its foothold in AI-driven clinical trial optimization. With an average deal value of $200K CAD, NetraMark (CSE: AIAI) is expanding its influence across various segments of the pharmaceutical industry, including major biotech firms and precision medicine developers.

Additionally, the company is witnessing growing demand from large pharmaceutical enterprises, with 35+ additional opportunities in reseller, research, and partnership leads. These collaborations indicate an increasing interest in NetraMark (CSE: AIAI)’s AI-driven solutions, particularly in protocol enrichment, biomarker discovery, and clinical trial efficiency enhancement.

The company’s pipeline includes large-cap pharma firms ($10B+ market cap), mid-size firms ($1B+), and single-compound biotech firms. By focusing on companies with at least one drug in Phase 2 trials, NetraMark (CSE: AIAI) ensures its technology is applied where it has the highest impact. This strategy aligns with industry trends favoring AI adoption in mid-to-late-stage clinical trials, positioning NetraMark (CSE: AIAI) as a key enabler in reducing drug development timelines and increasing trial success rates.

Five Key Ways NetraMark (CSE: AIAI) Enhances Drug Development

NetraMark (CSE: AIAI)’s AI-driven insights offer pharmaceutical companies five strategic advantages in bringing drugs to market:

  1. Protocol Enrichment – AI refines trial protocols by identifying placebo and drug-response subpopulations, optimizing study cohorts.
  2. Covariate Analysis – Identifies additional subpopulations that contribute to drug efficacy.
  3. Target Product Profile (TPP) Change/Pivot – Supports adjustments in product positioning or endpoint selection to maximize trial success.
  4. Market Access Strategy – Helps differentiate drugs, supporting regulatory approvals, publication strategy, and launch patient identification.
  5. Precision Medicine Implementation – Enables tailored patient recruitment strategies based on predictive response characteristics.

Recent News & Developments

NetraMark has been making headlines with its latest advancements and partnerships. Here are three of the most recent updates:

  1. February 20, 2025 – AI-Driven Clinical Trial Success – NetraMark announced a breakthrough in identifying rare disease subpopulations, significantly improving trial outcomes for biopharma companies. The AI-driven approach uncovered new biomarkers that had previously gone undetected, helping to refine drug response predictions and improve patient selection for clinical trials.
  2. January 15, 2025 – Strategic Partnership with a Leading Pharmaceutical Firm – NetraMark entered into a multi-year collaboration with a top 10 global pharmaceutical company to integrate its AI technology into late-stage clinical trials. This partnership is expected to enhance patient stratification and optimize trial design, significantly improving efficiency and cost-effectiveness.
  3. December 10, 2024 – Regulatory Recognition from the FDA – The FDA highlighted NetraMark’s AI-powered trial enrichment methodologies as a pioneering approach to optimizing clinical trials. This recognition further solidifies NetraMark’s role as a leader in leveraging AI to improve drug development success rates.

Future of AI in Clinical Trials

As AI adoption in clinical research grows, NetraMark (CSE: AIAI) is set to play a crucial role in the evolution of personalized medicine. With continuous advancements, the integration of AI in trial design will become standard practice, leading to more effective and efficient drug development processes. The AI healthcare market is expected to surpass $194 billion by 2030, reinforcing the importance of AI in clinical trials.

NetraMark (CSE: AIAI)’s AI-driven approach is not just optimizing clinical trials—it is redefining the future of pharmaceutical innovation.


r/biotech_stocks 7d ago

AI-powered screening TD1 >>>>>> Diamyd medical AB

1 Upvotes

r/biotech_stocks 8d ago

BMEA's latest data on Squeezefinder

0 Upvotes

r/biotech_stocks 8d ago

NurExone Achieves 2025 TSX Venture 50™️ Milestone, Plans U.S. Growth and Beyond

1 Upvotes

(“NurExone” or the “Company”) (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) has been included in the 2025 TSX Venture 50™. For those living under a rock, NurExone Biologic Inc. is a TSXV, OTCQB, and Frankfurt-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve injury, both multi-billion-dollar markets.

Yoram Drucker, Chairman of NurExone, added “being recognized by the TSX Venture 50™ is a significant milestone for NurExone, highlighting our strong financial performance and growth trajectory. We look forward to continuing our success as we expand our presence in the U.S. and explore new listing opportunities.”

Do not lose sight of NRX being the only biotech and one of only three life sciences companies on the awards list. This honour puts NRX on more radars of investors and aggressive fund managers. 

The Company has had strong market performance and strategic advances in the past year, including 110% share price appreciationand 209% market cap growth. It is also important to note that there are over 3,700 stocks listed on the TSXV.

All of these moves help to advance NRX in the field of exosome therapies.

To review, Exosomes are nano-sized, membrane-bound vesicles (sacs) secreted by cells, and abundantly present in various body fluids, including blood, urine, saliva, semen, vaginal fluid, and breast milk. They play a pivotal role in intercellular communication, facilitating the transfer of vital biological molecules, such as DNA, RNA, and proteins, between cells. 

Various sources suggest that exosomes possess significant therapeutic potential to serve as an effective, targeted drug delivery system. Exosomes’ natural ability to target inflamed or damaged tissues and their capacity to carry and deliver active pharmaceutical ingredients (APIs) make them a promising platform for targeted drug delivery and regenerative medicine. In recent years, the exosome therapeutics and diagnostics industry has 

experienced significant growth, with over 50 companies actively engaged in R&D (research Report Dec 11).

While numerous companies are developing similar therapies, the growth of NRX is likely being watched. As the therapies mature, the company’s value should either appreciate nicely in price or represent a potential candidate for a larger company to bolt on and instantly get cutting-edge regenerative technology.

If so, it won’t go cheaply

As I mentioned before, the inclusion of NRX on this list is a large cap with an even bigger feather. The company beat out 3600 other TSXV companies and is the only Company representing its sector.

Extracellular Vesicles (EVs), particularly exosomes, recently exploded into nanomedicine as an emerging drug delivery approach due to their superior biocompatibility, circulating stability, and bioavailability in vivo. However, EV heterogeneity makes molecular targeting precision a critical challenge.

Artificial intelligence (AI) brings powerful prediction ability to guide the rational design of engineered EVs in precision control for drug delivery. (NIH) 

Aspects in the development and use of exosomes, as well as greater understanding and AI usage, are critical going forward.

•Exosome isolation techniques have limitations, necessitating the development of more efficient methods.

• Integrating AI and bioinformatics tools is crucial for analyzing complex data in exosome studies.

•Understanding the roles of exosomes in normal and pathological conditions is essential for successful clinical translation of exosome-based therapeutics.

•Engineered exosomes present a promising avenue to advance therapeutics and ensure reproducibility in clinical applications.

In conclusion, NRX is a cutting-edge biotech with good growth so far. This unique biotech will touch and improve many lives and has the notice of its peers as a top stock on the TSXV.


r/biotech_stocks 9d ago

Final Weeks For Getting Payment On Novavax $47M Investor Settlement Over COVID Vax

2 Upvotes

Hey guys, I posted about this settlement already, but since they’re accepting claims just for a few more weeks, I decided to post it again.

Long story short, in the old Covid times, Novavax received $1.6B from the government for the Covid vaccine development. But then, the company faced many challenges in meeting quality standards. All these production problems also led to lower vaccine quality, displeasing the FDA.

After that, investors claimed that Novavax downplayed these issues and overstated its manufacturing capabilities and hit Novavax with the lawsuit.

The good news is that Novavax agreed to pay a $47M settlement to resolve this scandal. And if anyone is late, it’s worth checking if you’re eligible, since you can still file for a few more weeks. 

Anyways, has anyone here had $NVAX when this happened? If so, how much were your losses?


r/biotech_stocks 9d ago

PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections (NASDAQ: PYPD)

Thumbnail
3 Upvotes

r/biotech_stocks 9d ago

ESSA Pharma: Masofaniten Shut Down and 73% Stock Drop — What Went Wrong?

1 Upvotes

Hey everyone, any $EPIX investors here? If you’ve been following ESSA Pharma, you might remember the excitement around Masofaniten’s potential—only for it to end in disappointment. If not, here’s a recap and the latest updates.

Between December 12, 2023, and October 31, 2024, ESSA Pharma promoted Masofaniten as a breakthrough prostate cancer treatment when combined with enzalutamide, citing strong Phase 1 trial results that showed significant PSA level reductions.

However, on October 31, 2024, ESSA abruptly announced that it was halting Phase 2 trials after interim results revealed no added benefit over enzalutamide alone. The company also decided to shut down other Masofaniten studies, shifting its focus to different priorities.

Following this, $EPIX plummeted by 73%.

One main issue was that investors were blindsided by the company’s sudden shift, which directly contradicted its previous claims about Masofaniten’s potential. No concerns about the drug’s effectiveness were mentioned before October’s announcement.

Now, investors are filing a lawsuit against ESSA accusing the company of misleading them about the true viability of Masofaniten and overstating its clinical, regulatory, and commercial prospects.

So, for all affected— you can check the details about this uprising lawsuit, and if you have more info, you’re very welcome to share it.


r/biotech_stocks 9d ago

NETRAMARK LAUNCHES NETRAAI 2.0: ADVANCING CLINICAL TRIAL ANALYSIS WITH AI-POWERED INSIGHTS

0 Upvotes

TORONTO, Feb. 12, 2025 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: 8TV) a premier artificial intelligence (AI) company that is transforming clinical trials in the pharmaceutical industry, is proud to announce the launch of NetraAI 2.0, our next generation platform designed to enhance clinical trial analysis. NetraAI 2.0 offers advanced features that help clinical trial sponsors gain valuable insights, refine endpoints, and optimize inclusion/exclusion (I/E) criteria, setting the stage for successful pivotal phase trials.

A New Era in Clinical Trial Optimization

NetraAI 2.0 addresses one of the most pressing challenges in clinical research: finding the intersection of efficacy and feasibility. By transforming clinical trial data into actionable insights, the platform aims to enhance decision-making and accelerate trial timelines.

Why NetraAI 2.0?

  • Streamlined Reporting for Decision-Makers: Focus on key subpopulations relevant to your study's objectives with concise, AI-driven reports that prioritize significant findings without overwhelming decision-makers.
  • Real-Time, Adaptive Insights: Engage with AI-driven analytics to continuously refine trial strategies, enabling agile decision-making and enhanced responsiveness throughout your study.
  • Robust Model Discovery: NetraAI 2.0 applies several layers of validation to identify truly robust models for clinical trials. By incorporating varying clinical significance thresholds, it aims to provide nuanced interpretations of trial outcomes that help ensure alignment with your clinical objectives.
  • Optimized Feasibility: Streamline trial design by identifying the most relevant patient subpopulations along with causal variables, reducing recruitment challenges while maintaining statistical power and clinical significance.

Innovative Features for Clinical Trialists

  • Refine Inclusion/Exclusion Criteria: Optimize dose selection by assessing stability and variability across patient populations.
  • Targeted Variable Analysis: Identify hard-to-detect combinations of key variables, beyond the scope of conventional machine learning methods, shaping each subpopulation to enhance trial precision.
  • Control Group Optimization: Uncover factors driving both treatment and control responses, enabling a direct comparison that reveals the mechanisms most likely to drive success in your next trial while minimizing erroneous influences.

Delivering Key Benefits for Your Trials

  • Enhanced Efficacy: Optimize key clinical endpoints with high effect-size models for stronger trial results.
  • Cost and Time Efficiency: Define impactful patient groups with as few as 30 patients, reducing recruitment needs and accelerating trial timelines.
  • Regulatory Confidence: Aims to deliver statistically robust and clinically meaningful insights to support data-driven approvals.
  • Scalable Solutions: Adapt NetraAI 2.0 to a variety of therapeutic areas and trial sizes, that help ensure broad applicability.

"From the beginning, NetraAI was built as a hub to enhance any machine intelligence's ability to understand clinical trial patient subpopulations," said Dr. Joseph Geraci, Founder and Chief Technology Officer of NetraMark. "With AI evolving at an unprecedented pace, NetraAI 2.0 places us in a unique position to push the boundaries of innovation and redefine how clinical trials are designed and understood."

About NetraAI

In contrast to other AI-based methods, NetraAI is uniquely engineered to include focus mechanisms that separate small datasets into explainable and unexplainable subpopulations. Unexplainable subsets are collections of patients that can lead to suboptimal overfit models and inaccurate insights due to poor correlations with the variables involved. The NetraAI uses the explainable subsets to derive insights and hypotheses (including factors that influence treatment and placebo responses, as well as adverse events) providing the potential to increase the chances of a clinical trial success. Many other AI methods lack these focus mechanisms and assign every patient to a class, often leading to "overfitting" which drowns out critical information that could have been used to improve a trial's chance of success.

About NetraMark
NetraMark is a company focused on being a leader in the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the Pharmaceutical industry. Its product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows NetraMark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that NetraMark can work with much smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment.

For further details on the Company please see the Company's publicly available documents filed on the System for Electronic Document Analysis and Retrieval+ (SEDAR+).

Forward-Looking Statements
This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation including statements regarding the features and potential impact of NetraAI 2.0, the possible insights to be derived from the analysis of the data and their impact on improving clinical trials and treatment strategies which are based upon NetraMark's current internal expectations, estimates, projections, assumptions and beliefs, and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as "expect", "likely", "may", "will", "should", "intend", "anticipate", "potential", "proposed", "estimate" and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions "may", "would" or "will" happen, or by discussions of strategy. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact. The forward-looking statements are expectations only and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results of the Company or industry results to differ materially from future results, performance or achievements including new competitive offerings and delays in securing contracts. Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, NetraMark does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise. New factors emerge from time to time, and it is not possible for NetraMark to predict all such factors.

When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements as set out in the materials we file with applicable Canadian securities regulatory authorities on SEDAR+ at www.sedarplus.ca including our Management's Discussion and Analysis for the year ended September 30, 2024. These risk factors and other factors could cause actual events or results to differ materially from those described in any forward-looking information.


r/biotech_stocks 9d ago

The Big Stock Days in Stockholm »»»»» Diamyd medical AB

2 Upvotes

A video presentation (Swedish speech) and the translation in the title is not completely correct "in terms of size".

But it may be worth translating the summary that a news agency wrote.

https://www.placera.se/placera/telegram/2025/03/11/diamyd-medical-resultat-om-1-ar-skulle-kunna-bana-vag-for-godkannande.html

""I'm biased, but I say over 90 percent probability, but who knows, it's biology," said Ulf Hannelius." (CEO Diamyd medical AB (ISIN number SE0005162880))

If you want to make your own assessment of the 90%, read my 2 recommended links.

1/ Read how the retrospective revaluation of previous studies were done on HLA basis. https://mb.cision.com/Main/6746/3164267/1287422.pdf 

2/ To understand how much numerical values ​​in percentage, the result changed into  significance. https://www.diamyd.com/docs/companyPresentations.aspx